nach oben

High Blood Pressure & Cardiovascular Prevention

Erschienen in:

01.12.2015 | Commentary

Use of Fixed Combination Therapies to Improve Blood Pressure Control in the Clinical Management of Hypertension: A Key Opportunity

verfasst von: Giuliano Tocci, Agostino Virdis

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Excerpt

Hypertension is a major modifiable risk factor, which significantly and independently increases the risk of developing cardiovascular and renal complications [1]. Pharmacological treatment of hypertension aimed at achieving the recommended therapeutic targets [i.e. blood pressure (BP) levels below 140/90 mmHg] substantially reduces the risk of complications in different clinical settings [2]. Despite these benefits, worldwide rates of BP control are still reported to be largely unsatisfactory, thus contributing to a persistently high burden of hypertension-related diseases [3, 4]. …

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.CrossRefPubMed

Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35.CrossRefPubMed

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.

Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377(9765):568–77.CrossRefPubMed

Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7):1584–90.CrossRefPubMed

Elley CR, Gupta AK, Webster R, Selak V, Jun M, Patel A, et al. The efficacy and tolerability of ‘polypills’: meta-analysis of randomised controlled trials. PloS One. 2012;7(12):e52145.PubMedCentralCrossRefPubMed

Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.CrossRefPubMed

Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.CrossRefPubMed

Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.

10.

Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.

11.

Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.CrossRefPubMed

12.

Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–8.CrossRefPubMed

13.

Group PC. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–41.CrossRef

14.

Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.CrossRefPubMed

15.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.CrossRefPubMed

16.

Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, et al. 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev. 2013;20(1):45–52.CrossRefPubMed

17.

Karpov YA, Gorbunov VM, Deev AD. Effectiveness of fixed-dose perindopril/amlodipine on clinic, ambulatory and self-monitored blood pressure and blood pressure variability: an open-label, non comparative study in the general practice. High Blood Press Cardiovasc Prev. 2015. doi:10.1007/s40292-015-0117-0.PubMed

Titel: Use of Fixed Combination Therapies to Improve Blood Pressure Control in the Clinical Management of Hypertension: A Key Opportunity
verfasst von: Giuliano Tocci
Agostino Virdis
Publikationsdatum: 01.12.2015
Verlag: Springer International Publishing
Erschienen in: High Blood Pressure & Cardiovascular Prevention / Ausgabe 4/2015
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-015-0118-z

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Use of Fixed Combination Therapies to Improve Blood Pressure Control in the Clinical Management of Hypertension: A Key Opportunity

Excerpt

Neu im Fachgebiet Kardiologie

Schadet Ärger den Gefäßen?

Intervallfasten zur Regeneration des Herzmuskels?

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Kardiologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Structural and Functional Abnormalities of Carotid Artery and Their Relation with EVA Phenomenon

Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach

Effectiveness of Fixed-Dose Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice

Arterial Stiffness in a Rural Population of Argentina: Pilot Study

Safety and Clinical Outcome of the Delivery of Radiofrequency Nerve Ablation Therapy in a Renal Artery of Unusual Anatomy

Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues

Neu im Fachgebiet Kardiologie

Schadet Ärger den Gefäßen?

Intervallfasten zur Regeneration des Herzmuskels?

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Kardiologie